AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12127032
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine (CM)
Trial: 12127032
Drug: Intermittent morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent morphine (IM)
Trial: 28854065
Drug: Thalidomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100 mg twice daily on days 1 to 5) with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8 mg on days 2 to 4)
Trial: 28854065
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8 mg on days 2 to 4)
Trial: 24606087
Drug: Low-dose rhIGF-I/rhIGFBP-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose rhIGF-I/rhIGFBP-3 (30 mg/d)
Trial: 24606087
Drug: High-dose rhIGF-I/rhIGFBP-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rhIGF-I/rhIGFBP-3 (60 mg/d)
Trial: 15628646
Drug: In-patient psychotherapeutic
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-patient psychotherapeutic treatment with accompanying children
Trial: 15628646
Drug: In-patient psychotherapeutic
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-patient psychotherapeutic treatment without accompanying children
Trial: 9230157
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin 81 mg
Trial: 9230157
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin 81 mg
Trial: 9230157
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin 325 mg
Trial: 9230157
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin 325 mg
Trial: 29050650
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard supplement)
Trial: 25262253
Drug: Indapamide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (1.5 mg Slow Release (SR)/day)
Trial: 19494558
Drug: Nutritional therapy,
RxNorm normalized name: nutritional therapy, ketogenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy, details not specified
Trial: 1672493
Drug: Intranasal cromolyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cromolyn sodium, 1 spray in each nostril QID for 4 weeks
Trial: 1672493
Drug: Oral terfenadine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terfenadine, 60 mg BID for 4 weeks
Trial: 1672493
Drug: Intranasal cromolyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cromolyn sodium
Trial: 7037487
Drug: Metergoline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metergoline (10 mg daily for two days plus a 4 mg dose 1 hour before the post-treatment test)
Trial: 24811201
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (n=182)
Trial: 24811201
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (n=180)
Trial: 21062541
Drug: Psychologically informed
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychologically informed sessions based on cognitive-behavioural therapy or person-centred counselling principles
Trial: 2851181
Drug: Cisplatin 120
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 120 mg/m2 every 4 weeks and vindesine 3 mg/m2 weekly
Trial: 2851181
Drug: Cisplatin/vindesine (chemotherapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/vindesine (chemotherapy)
Trial: 31993658
Drug: Distress Tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distress Tolerance Treatment (DT-W)
Trial: 27030088
Drug: Liothyronine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liothyronine 15 μg for two weeks, then 30-45 μg for four weeks
Trial: 27030088
Drug: Liothyronine 30-45
RxNorm normalized name: LEVOTHYROXINE NA 180MCG/LIOTHYRONINE NA 45MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liothyronine 30-45 μg
Trial: 27030088
Drug: Liothyronine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liothyronine therapy
Trial: 15961567
Drug: Early headgear
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early headgear (HG) treatment initiated immediately
Trial: 15961567
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups underwent orthodontic therapy including fixed appliances and possible extractions when necessary
Trial: 10233492
Drug: L-arginine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (5 g/day)
Trial: 1760424
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate (NEA) 1 mg + ethinyl oestradiol (EE) 50 micrograms
Trial: 30981629
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (1000 mg, n = 86)
Trial: 30981629
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (II) fumarate (100 tablets of 100 mg [10 per week], n = 90)
Trial: 19172098
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg) twice a week for 4 months
Trial: 19172098
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 patients with ED who did not take any treatment)
Trial: 15710092
Drug: Gabapentin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (up to 3,600 mg/day)
Trial: 12213867
Drug: Nateglinide 30
RxNorm normalized name: nateglinide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 30 mg
Trial: 12213867
Drug: Nateglinide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (all doses)
Trial: 3781675
Drug: Propranolol, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 40 mg t.i.d.
Trial: 3781675
Drug: Diltiazem, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 60 mg t.i.d.
Trial: 24237386
Drug: Dapagliflozin 5
RxNorm normalized name: dapagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 5 mg once daily for 12 weeks
Trial: 22726914
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral smoking cessation treatment (CBT)
Trial: 24446953
Drug: BRV 5
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BRV 5 mg/day
Trial: 24446953
Drug: BRV 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRV 20 mg/day
Trial: 18824852
Drug: Intermittent pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pantoprazole infusion
Trial: 18824852
Drug: Continuous pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous pantoprazole infusion
Trial: 8458598
Drug: L-Dopa (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dopa (300 mg total: 50 mg at 9 am, 100 mg before lunch, 150 mg before dinner)
Trial: 3752422
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg lormetazepam
Trial: 3752422
Drug: 0.02 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg/kg flunitrazepam
Trial: 30666823
Drug: Belimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab (10 mg/kg) plus azathioprine (2 mg/kg/day) and low-dose oral glucocorticoids (≤10 mg/day)
Trial: 30666823
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus azathioprine (2 mg/kg/day) and low-dose oral glucocorticoids (≤10 mg/day)
Trial: 30666823
Drug: Belimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab (10 mg/kg)
Trial: 30020423
Drug: S-ketamine (0.006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (0.006 mg/kg/min)
Trial: 22168398
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg bupropion
Trial: 22168398
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg bupropion
Trial: 22168398
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg bupropion
Trial: 19187813
Drug: Residential Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential Cognitive Therapy (RCT)
Trial: 18846473
Drug: Residential Interpersonal
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential Interpersonal Therapy (RIPT)
Trial: 15315717
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg, single oral dose)
Trial: 15315717
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/d, repeated dosing for 2 weeks)
Trial: 11449834
Drug: Multidisciplinary pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary pain treatment (MPT)
Trial: 10399516
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hyperbaric bupivacaine plus 25 micrograms fentanyl (0.5 ml) and cerebrospinal fluid (CSF) 0.6 ml (Group M + F)
Trial: 10399516
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg hyperbaric bupivacaine plus 0.5 ml of CSF (Group M)
Trial: 8002551
Drug: Overtraining group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overtraining group (OT); weight trained legs daily for 2 weeks with 100% 1 repetition maximum
Trial: 3244794
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg PLG i.v.
Trial: 27477844
Drug: GMZ2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMZ2 vaccine (100μg adjuvanted with aluminum hydroxide)
Trial: 27477844
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (rabies)
Trial: 27477844
Drug: GMZ2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMZ2 vaccine
Trial: 23698199
Drug: 0.2% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% levobupivacaine with 2 Mi g/ml fentanyl
Trial: 23698199
Drug: 0.1% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% levobupivacaine with 2 Mi g/ml fentanyl
Trial: 20861739
Drug: ramelteon (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramelteon (8 mg/day)
Trial: 9892876
Drug: pumaprazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pumaprazole (100 mg b.d.)
Trial: 9892876
Drug: omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole (20 mg o.d.)
Trial: 26536019
Drug: Memantine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10 mg/day initially and 20 mg/day at the end of the first week)
Trial: 23314272
Drug: Peptide/CAF01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide/CAF01 vaccine
Trial: 21980373
Drug: Single-dose mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose mebendazole (500 mg)
Trial: 21980373
Drug: Triple-dose albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple-dose albendazole (3×400 mg over 3 consecutive days)
Trial: 21980373
Drug: Triple-dose mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple-dose mebendazole (3×500 mg over 3 consecutive days)
Trial: 21980373
Drug: Triple-dose mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple-dose mebendazole
Trial: 21980373
Drug: Single and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and triple doses of either drug
Trial: 21980373
Drug: Triple-dose regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-dose regimens
Trial: 2138925
Drug: Single-dose regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose regimens
Trial: 19570098
Drug: Oral dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dietary supplement containing antioxidants, minerals and glycosaminoglycans
Trial: 18162024
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg q.a.m.
Trial: 18162024
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg q.a.m.
Trial: 18162024
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg b.i.d.
Trial: 18162024
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg q.a.m. (with food)
Trial: 18162024
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg b.i.d. (with food)
Trial: 18162024
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg q.a.m. (with food)
Trial: 18162024
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg q.a.m. without food
Trial: 18162024
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg b.i.d. without food
Trial: 18162024
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg q.a.m. without food
Trial: 15181401
Drug: Sevoflurane administration
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane administration for 15 min before coronary occlusion
Trial: 15181401
Drug: No sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No sevoflurane administration (Control group)
Trial: 24486335
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron 4 mg
Trial: 3434165
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local treatment
Trial: 28400446
Drug: Avacopan (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avacopan (30 mg, twice daily) plus reduced-dose prednisone (20 mg daily)
Trial: 28400446
Drug: Avacopan (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avacopan (30 mg, twice daily) without prednisone
Trial: 28400446
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus prednisone (60 mg daily)
Trial: 25043459
Drug: Teriparatide 20 µg
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide 20 µg daily
Trial: 25043459
Drug: Denosumab 60 mg
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab 60 mg every 6 months
Trial: 23549780
Drug: quasi-volumetric modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quasi-volumetric modulated arc therapy (qVMAT)
Trial: 23549780
Drug: intensity-modulated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intensity-modulated radiation therapy (IMRT)
Trial: 23549780
Drug: 3D-conformal radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D-conformal radiation therapy (3D-CRT)
Trial: 10666534
Drug: Vibration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration therapy (60 Hz frequency, 45-min treatment)
Trial: 10666534
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (audible hum and lit control box without vibration)
Trial: 10666534
Drug: Vibration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration therapy vs. Sham treatment
Trial: 9327190
Drug: etodolac 200
RxNorm normalized name: etodolac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etodolac 200 mg
Trial: 9327190
Drug: acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen plus codeine (Tylenol #3)
Trial: 8380310
Drug: Estrogen pretreatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen pretreatment (2.5 mg of conjugated estrogen, Premarin)
Trial: 3533271
Drug: L-5-hydroxytryptophan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan (5 mg/kg body weight)
Trial: 28881387
Drug: Lactoferrin (LF)
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin (LF) and lactoperoxidase (LPO) containing tablets
Trial: 25987323
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) treatment during double-blind trials and a 6-month open-label phase
Trial: 9284855
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (4 micrograms/kg/min) + low-dose furosemide (80 mg/day)
Trial: 9284855
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (4 micrograms/kg/min) + medium-dose furosemide (5 mg/kg/day)
Trial: 9284855
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (10 mg/kg/day)
Trial: 18075922
Drug: Brief intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief intervention package for hazardous drinkers; details on dosage and duration not specified.
Trial: 15077240
Drug: Zydis selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zydis selegiline 1.25 mg
Trial: 15077240
Drug: Zydis selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zydis selegiline 2.5 mg
Trial: 10214571
Drug: ADCON‐L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADCON‐L
Trial: 7251221
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen treatment (20 mg twice daily for 2 years)
Trial: 7251221
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant radiotherapy or chemotherapy
Trial: 23328162
Drug: Naftopidil (Naf)
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil (Naf) 50-75 mg once daily for 2 weeks followed by 75 mg once daily for 4 weeks
Trial: 23328162
Drug: Silodosin (Silo)
RxNorm normalized name: Silodosin
DrugBank: Silodosin (DB06207)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Silodosin (Silo) 2-4 mg twice daily for 2 weeks followed by 4 mg twice daily for 4 weeks
Trial: 15469803
Drug: Oral deflazacort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral deflazacort (1.5 mg/kg) for 7 days
Trial: 15469803
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (1 mg/kg) for 7 days
Trial: 10399518
Drug: Epidural block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural block (caudal) with 11-15 ml of 2% lidocaine
Trial: 30362137
Drug: Extra-short implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-short implants (≤6 mm)
Trial: 30362137
Drug: Long implants
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long implants (≥10 mm)
Trial: 29349999
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of Diprospan, Lidocaine, and Mecobalamine after PELD
Trial: 29349999
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection after PELD
Trial: 29349999
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (PELD with and without epidural injection)
Trial: 23702610
Drug: Ahmed valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ahmed valve implant surgery with combined short scleral tunnel with Tenon advancement and duplication technique
Trial: 23702610
Drug: AGV implant
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGV implant surgery without patch graft